Zhao, Xiaojuan http://orcid.org/0000-0002-0526-7666
Alibhai, Dominic http://orcid.org/0000-0001-5421-4424
Walsh, Tony G. http://orcid.org/0000-0002-0403-3999
Tarassova, Nathalie
Englert, Maximilian http://orcid.org/0000-0002-9066-5801
Birol, Semra Z.
Li, Yong http://orcid.org/0000-0001-6266-8717
Williams, Christopher M.
Neal, Chris R.
Burkard, Philipp http://orcid.org/0000-0001-9748-7967
Cross, Stephen J. http://orcid.org/0000-0003-3565-0479
Aitken, Elizabeth W.
Waller, Amie K.
Beltrán, José Ballester http://orcid.org/0000-0002-3287-2925
Gunning, Peter W. http://orcid.org/0000-0003-0833-3128
Hardeman, Edna C. http://orcid.org/0000-0003-1649-7712
Agbani, Ejaife O. http://orcid.org/0000-0002-0043-9115
Nieswandt, Bernhard http://orcid.org/0000-0003-1454-7413
Hers, Ingeborg
Ghevaert, Cedric
Poole, Alastair W. http://orcid.org/0000-0002-0868-297X
Funding for this research was provided by:
Wellcome Trust (219472/Z/19/Z)
British Heart Foundation (RG/15/16/31758, PG/16/102/32647, PG/21/10760, SP/F/21/150023, PG/16/102/32647, SP/F/21/150023, SP/F/21/150023)
Deutsche Forschungsgemeinschaft (374031971 - TRR 240/project A01)
Wellcome Trust (219472/A/19/Z)
Article History
Received: 23 November 2022
Accepted: 20 June 2023
First Online: 7 July 2023
Competing interests
: P.W.G. and E.C.H. receive funding from TroBio Therapeutics, a company commercialising tropomyosin-targeting drugs. P.W.G. and E.C.H. are directors and shareholders of TroBio. All other authors declare no competing interests.